Epiodyne is structured around development of small molecule medicines designed for patients with opioid use disorder. Based upon novel insights into GPCR receptor pharmacology that were uncovered by leading researchers at UCSF, Stanford and Duke, the firm's products target the brain's opioid peptide system to restore the function of the brain reward system to treat conditions such as compulsivity, self-injury and addiction, improving the lives of patients with psychiatric and neurological disorders. Quantitative pharmacological and behavioral techniques are being employed to translate insights into novel medicines for patients with opioid use disorder (OUD).
